Showing results (811-820 of 1,188) with videos related to

Sort By:
Pageof 119
Leukemia Research|January 19, 2016
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agentsAziz Nazha, Mikkael A Sekeres, Guillermo Garcia-Manero, et al.
Blood|August 25, 2017
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatmentGhayas C Issa, Hagop M Kantarjian, Graciela Nogueras Gonzalez, et al.
Cancer|April 9, 2024
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemiaElias Jabbour, Fadi G Haddad, Koji Sasaki, et al.
Blood Cancer Journal|May 6, 2020
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotypeBachar Samra, Guillaume Richard-Carpentier, Tapan M Kadia, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 19, 2020
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 AbnormalitiesDavid A Sallman, John Barnard, Najla H Al Ali, et al.
Blood Advances|December 31, 2021
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromesAmer M Zeidan, Isaac Boss, C L Beach, et al.
Cancer|October 12, 2018
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvageElias Jabbour, Koji Sasaki, Farhad Ravandi, et al.
Cancer|May 17, 2002
Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent courseSrdan Verstovsek, Hui Lin, Hagop Kantarjian, et al.
Cancer|January 23, 2019
Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemiaHagop M Kantarjian, Elias J Jabbour, Guillermo Garcia-Manero, et al.
The Lancet. Haematology|December 4, 2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 studyElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Pageof 119